Download Funding News

Funding News
January 2, 2007
NEWS & NOTICES FROM WEEKS ENDING DECEMBER 22 & 29
NIH NIDCR Intends to Participate in High Priority, Short-Term Project Award – R56 (12/28)
Effective immediately, NIDCR will join NCI and the other nine institutes in sponsoring this program.
NIH Program Withdrawals
• NRCC from Chronic Fatigue Syndrome: Pathophysiology and Treatment (12/28)
• NEI from Brain Disorders in the Developing World: Research Across the Lifespan – R01 (12/22)
NIH: New Contact Person for Understanding the Mechanisms of Health Risk Behavior
Change in Children and Adolescents – R01, R02 (12/22)
Direct questions regarding PA-07-148 (end date 7/6/07) and PA-04-121 (end date 1/3/07) to Dr. Amy Yaroch.
For more information, see NOT-CA-07-007.
NIH NIDA Changes Receipt Dates for Cutting-Edge Basic Research Awards (CEBRA) – R21
(12/21) Receipt dates for CEBRA R21 applications (PAR-06-209) changed to standard standing receipt
dates (February 16, October 16), effective this February. Receipt dates for AIDS/AIDS-related applications
remain May 1 and January 2. For a complete list of mechanism-specific receipt dates, see
NOT-OD-07-001.
NIH NIGMS Extends Initial Deadline for Collaborations with National Centers for Scientific
[Biomedical] Computing – R01, R21 [PAR-07-249, PAR-07-250] (12/21)
January 17, 2007 receipt date extended to February 15. Subsequent receipt dates remain as May 17, 2007
and January 17, 2008. Program described in RECENT SOLICITATIONS (next section).
NIH NIDCR Clarifies Research Objectives for Exploratory and Developmental Grants in
Clinical Research – R21 (12/21)
Studies including basic or preclinical research are not appropriate for this initiative (PAR-06-246); instead, use
the parent R21 solicitation (PA-06-181).
NIH Issues New PAR for Dissemination and Implementation Research in Health – R01 (12/21)
As of January 2, researchers should apply through PAR-07-086 using the SF424 forms contained therein.
NIH OSSR/NIDA Publishes FAQs for Facilitating Interdisciplinary Research via
Methodological and Technological Innovation in the Behavioral and Social Sciences – R01
(12/20) In addition to current information about this NIH Roadmap Initiative, this notice (NOT-RM-07-004)
provides instructions on how to sign up for program updates.
NIH Clarifies Late-Submission Policy for Multiple-PI Proposals [NOT-OD-07-026] (12/6)
On a situational basis, NIH will consider late submissions for projects with multiple PD/PIs. An acceptable
situation would be that a PD/PI served on an NIH extramural peer review group during the time he/she was
expected to work on the application. In such cases, NIH could effect a grace period of up to (a) two weeks
for applications with regular standing receipt dates or (b) one-week for applications having expedited
receipt dates.
Susan G. Koman Foundation Baton Rouge Affiliate Appoints New Grants Chair (12/22)
Sandy Betz has informed me that Gloria Dorsey will become the new grants chairwoman as of March 31.
Tulane University to Host NSF Day on January 26
This one-day introduction to NSF is scheduled from 7:30 AM to 4:00 PM in the Lavin-Bernick Center for
University Life. No registration fee, but you should pre-register by January 19.
RECENT SOLICITATIONS
NIH NIA/NIDDK/NCI/NIEHS The Role of Nuclear Receptors in Tissue and Organismal Aging –
R01 [PAS-07-267] (12/22)
Opening Date:
Receipt Dates:
Closing Date:
January 5
February 5, June 5, and October 5 (standard)
May 2, 2009
Solicits research into (a) the underlying biologic mechanisms that involve nuclear receptors, their coregulators, and intracellular signaling systems in the process of aging, and (b) the connections between the
aging process and pathophysiology in middle and old age.
NCI’s wants to further understand the role of nuclear hormone receptor superfamily as well as the orphan
nuclear receptors, their coactivators/corepressors, in a number of human malignancies such as thyroid,
lung, colon, pancreas, endometrium, ovary, breast, and prostate. Areas of high cancer relevance include
understanding the role of the coregulators in the processes of:
• regulating transcription by modifying chromatin and/or associated proteins;
• influencing epithelial-stromal interactions during cancer progression;
• contributing to hormone resistance; and
• determining therapeutic response.
Commitment:
Renewable?
$1.2 M estimated for FY 2007
Yes
NIH NCI/NEI/NHLBI/NHGRI/NIA/NIAAA/NIAMS/NIBIB/NICHD/NIDCD/NIDCR/NIDA/NIEHS/
NIGMS/NIMH/NINDS/NINR Nanoscience and Nonotechnology in Biology and Medicine –
R01, R21 [PAR-07-033],[PAR-07-034] (12/27,12/28)
Opening Date:
Receipt Dates:
Closing Date:
Earliest Start Dates:
February 20
February 20, June 20, and October 22
January 31, 2010
December, April, July
Promotes the development of novel and more sophisticated approaches for the diagnosis, treatment and
management of an array of diseases and traumatic injuries. Research should address the challenge of
determining the “assembly instructions” for a cell and then implementing these instructions to generate
synthetic cellular components at the nanoscale.
Areas of NCI Interest
• Early detection of the disease using imaging
• In vitro early diagnostics: multiplexed sensitive and specific sensors
• Multi-functional therapeutics and localized therapy delivery
• Tools and approaches to interrogate, understand and manipulate single cells, structures and molecules
Research
Requirements:
Renewable?
Must involve the development of technology or application elements specific to
biological processes. Utilizing commercial nanotechnology to study biological
processes would not be sufficient.
Yes. Competing renewal applications accepted for both award mechanisms.
NIH NCRR/NCI/NHLBI/NIA/NIDA/NIDCR/NIDDK/NIEHS/NIGMS/NIMH/NINDS/ODS
Networks and Pathways Collaborative Research Projects – R01 [PA-07-266] (12/22)
Opening Date:
Receipt Dates:
Closing Date:
January 5
February 5, June 5, and October 5 (standard)
September 2, 2009
2
Funds research projects designed to leverage and complement ongoing technology development being
pursued in the National Technology Centers for Networks and Pathways (TCNPs), an NIH Roadmap Initiative.
Applicants may request support for their own work as well as supplemental support for components pursued
in the participating TCNP.
Award:
$150-250K (anticipated)
NIH NCI Immunoregulation of Gastrointestinal Carcinogenesis – R01, R21
[PA-07-256, PA-06-290] (12/21/07, 3/29/06)
Opening Date:
Receipt Dates:
Closing Date:
January 5 (R01), May 2, 2006 (R21)
February 5, June 5, and October 5 (standard R01)
February 16, June 16, and October 16 (standard R21)
May 2, 2009
Focuses on two aspects of gastrointestinal carcinogenesis, which include:
(1) the roles of the mucosal immune system in initiating and maintaining inflammatory responses that
contribute to the development of premalignant and malignant gastrointestinal cancers; and/or
(2) the molecular mechanism(s) by which immunoregulatory cells dampen inflammation and decrease
tumorigenesis.
Proposed research should further our understanding of how the unique gastrointestinal microenvironment
shapes mucosal immune responses in the setting of inflammatory disease-associated carcinogenesis.
Through this initiative, NIH seeks to gain a more comprehensive understanding of how the innate and
adaptive immune responses participate in gastrointestinal carcinogenesis.
NIH NCI/NIDDK/NIBIB/NIAAA Etiology, Prevention and Treatment of Hepatocellular
Carcinoma (HCC) – R01, R21 [PA-07-258, PA-06-295] (12/21, 3/29/06)
Opening Date:
Receipt Dates:
Closing Date:
January 5 (R01), May 2, 2006 (R21)
February 5, June 5, and October 5 (standard R01)
February 16, June 16, and October 16 (standard R21)
September 2, 2008 (R01), May 2, 2008 (R21)
Solicits research that addresses the etiology and etiologic mechanisms of hepatocellular carcinoma (HCC)
and the development of animal models, novel approaches to prevent this malignancy, and therapeutic or
diagnostic studies aimed at (a) establishing reliable prognostic indicators for disease progression and/or
(b) minimizing morbidity and mortality associated with this malignancy.
Similar in scope to the NCI-issued PA-05-138, based on P01 funding mechanism.
ROADMAP
INITIATIVE
NIH NCI Collaborations with National Centers for Biomedical Computing – R01, R21
[PAR-07-249, PAR-07-250] (12/20,12/21)
Opening Date:
Receipt Dates:
Closing Date:
January 15
February 15, May 17, and January 17
January 18, 2008
Funds projects from individual investigators or small groups to collaborate with the NIH Roadmap for
National Centers for Biomedical Computing (NCBCs)..
Research Restrictions:
Requires letter of support from the PI of the collaborating NIH NCBC. Project must
be completed by end of NCBC funding period.
NIH NCI Understanding the Effects of Emerging Cellular, Molecular and Genomic
Technologies on Cancer Health Care Delivery – R01, R21 [PA-07-260, PA-06-281]
(12/21, 3/29/06)
Opening Date:
Receipt Dates:
Closing Date:
January 5 (R01), May 2, 2009 (R21)
February 5, June 5, and October 5 (standard R01)
February 16, June 16, and October 16 (standard R21)
January 3, 2009 (R01), March 2, 2009 (R21)
3
Promotes health services research addressing utilization of cellular, molecular and genetic or genomic
(CMG) technologies in cancer care. Funds studies that assess CMG technologies in relation to: quality of
care; organizational barriers and change factors in utilization; cost/cost-effectiveness; disparities in access
and efficacy; monitoring of cross-sectional patterns of care and time trends; impact on existing standards of
care; and influence on outcomes such as incidence, progression, mortality, survival, and quality of life.
Specifically encourages:
(1) research on commercially available CMG clinical tools already in use, as well as experimental tools in
the later stages of development and/or in the regulatory approval pipeline; and
(2) interdisciplinary collaborations between health services researchers and those in the clinical and/or
translational sciences.
NIH NHLBI Ancillary Studies in Clinical Trials – R01 [RFA-HL-07-009] (12/21)
Opening Date:
LOI Receipt Date:
Receipt Dates:
Closing Date:
January 13
January 13
February 13, May 14, and September 17
September 18
Promotes time-sensitive studies that are ancillary to ongoing clinical trials related to heart, lung and blood
diseases and sleep disorders. Proposed study can address any NHLBI mission-related research question for
which the parent study can provide participants, infrastructure and data. Parent study need not be address
NHLBI’s mission or be supported by NIH. Applications must demonstrate the time-sensitive nature of their
proposal. Junior faculty members are encouraged to apply.
Potential Areas of Focus
• Basic physiologic, cellular and genetic mechanisms
• The basis for therapeutic benefits from interventions
• Biomarkers
• Quality of life and patient education materials
• Economic implications of the disease and its treatment
• New statistical methodology for the study design or data analysis
Award:
Intended Commitment
PI/PD Restrictions:
Research Restrictions:
Up to $1M over 4 years
$2.8M in 2007 (7-8 new grants), $4.2 million in FY 2008 (11-12 new grants), and
$1.4 million in FY 2009 (3-4 new grants)
Cannot be PI/PD of parent study
Must document permission from parent study to use the patient cohorts, data and
biological materials. Must not interfere with the parent study or unduly burden
participants. Must follow approved procedures and policies from parent study.
DIETRELATED
▲NIH NCI/NIAAA Molecular Approaches to Diet and Pancreatic Cancer Prevention – R01
[PA-07-257] (12/21)
Opening Date:
Receipt Dates:
Closing Date:
January 5
February 5, June 5, and October 5 (standard)
November 6
Solicits proposals of innovative preclinical and clinical research designed to determine how dietary energy
intake and bioactive food components, including alcohol, influence pancreatic cancer development and
prevention. Encourages collaboration between nutritional scientists and cancer biologists, oncologists, and
gastroenterologists to jointly examine key mechanisms in the pancreatic cancer process. Research should
attempt to establish mechanistic links between quantity and form of energy consumed and/or bioactive food
component intakes with pancreatic tumor incidence and behavior.
Emphasizes research involving possible mechanisms leading to pancreatic cancer: insulin signaling
pathways, the impact of glycated proteins, free radical damage, and aberrant methylation processes.
Understanding the underlying molecular, biochemical and cellular mechanisms by which alcohol ingestion
leads to the development of pancreatitis and subsequent pancreatic cancer risk is another relevant topic.
4
▲NIH NCI/NHLBI/NIA... Improving Diet and Physical Activity Assessment – R01, R21
[PAR-07-259, PAR-06-103] (12/21, 3/2/06)
Opening Date:
LOI Date (new apps):
Receipt Dates (“ ”):
Closing Date:
January 5 (R01), May 2, 2006 (R21)
January 5, September 5, May 5, 2008, and January 5, 2009 (R01)
May 1, January 1, September 1, May 1, 2008, and January 1, 2009 (R21)
February 5, October 5, June 5, 2008; February 5, 2009 (R01)
June 1, February 1, October 1, June 1, and February 1, 2009 (R21)
May 2, 2009 (R01), March 2, 2009 (R21)
This program aims to advance the quality of measurements of dietary intake and physical activity pertinent
to cancer and/or other pathologies by supporting research on improved instruments, technologies and/or
statistical/analytical techniques. Research plans should optimize the combined use of objective and selfreport measures in both general and diverse populations.
Intended to support innovative research focused on assessments of dietary and physical activity patterns,
not on the determinants of these behaviors. Not intended to produce minor adjustments to existing
instruments.
▲NIH NCI Exfoliated Cells, Bioactive Food Components, and Cancer – R01, R03, R21
[PA-07-207, PA-06-360, PA-06-359] (12/19, 4/13/06, 4/13/06)
Opening Date:
Receipt Dates:
Closing Date:
January 5 (R01), May 2, 2006 (R03, R21)
February 5, June 5, and October 5 (standard R01)
February 16, June 16, and October 16 (standard R03 & R21)
January 3, 2008
Promotes research that critically evaluates the use of exfoliated cells to monitor the physiological effects of
dietary bioactive food components thought to be involved with cancer prevention. Encourages
interdisciplinary collaborations between scientists engaged in research using exfoliated cells and those
conducting nutrition research related to cancer prevention.
Emphasis should be on comparing the activity of bioactive food components in exfoliated cells, normal cells
(such as the target tissue and blood cells), and, when available, tumor cells. Potential areas of investigation
include studying the effect of individual dietary components on molecular or biochemical processes (e.g.,
gene expression, DNA methylation, protein expression, and accumulation of bioactive food components)
and predicting the anticancer response in surrogate samples, blood, and its constituents and target tissues.
▲NIH NCI/NIDDK/NIBIB/NIA/OBSSR Research on the Economics of Diet, Activity, and Energy
Balance – R01, R21 [PA-07-205, PA-06-292] (12/19, 3/29/06)
Opening Date:
Receipt Dates:
Closing Date:
January 5 (R01), May 2, 2006 (R21)
February 5, June 5, and October 5 (standard R01)
February 16, June 16, and October 16 (standard R21)
January 3, 2008 (R01), November 2, 2007 (R21)
Created to make funding opportunities in the area of energy balance—i.e., the relationship between diet,
physical activity and obesity—known to researchers with expertise and experience in health economics and
health services. Aims to foster collaborative activities between these researchers and more traditional
researchers of cancer and other chronic diseases.
▲NIH NCI Diet-Induced Changes in Inflammation as Determinants of Colon Cancer – R01, R21
[PA-07-186, PA-06-283] (12/18, 3/28/06)
Opening Date:
Receipt Dates:
Closing Date:
January 5 (R01), May 2, 2006 (R21)
February 5, June 5, and October 5 (standard R01)
February 16, June 16, and October 16 (standard R21)
January 3, 2008 (R01), July 2, 2008 (R21)
Promotes research designed to (a) identify and characterize diet-induced changes in anti- and proinflammatory mediators that modulate colon cancer risk; (b) define genetic polymorphisms that modify the
response to specific bioactive food components with regard to colon cancer inhibition; and (c) unravel the
physiological effectiveness of dietary components in terms of concentration, activity, duration of exposure,
degree of stability, chemical forms, and binding affinity to receptors in inflammatory colonocytes.
5
Examples of Relevant Investigations
• Examining association(s) between the inhibition of pro-inflammatory mediators (e.g., TNF-α, NF-kB) and
the efficacy of resveratrol and curcumin on colon cancer cell growth rates
• Evaluating whether anti-inflammatory mediators (e.g., TGF-ß) might account for the effect of dietary
butyrate on colon tumor growth inhibition
• Evaluating whether polymorphisms in anti- or pro-inflammatory genes might explain the differential
responsiveness among individuals to dietary n-3 fatty acids with regard to colon cancer inhibition
• Examining whether the modulation of reactive oxygen species (ROS) and/or reactive nitrogen species
(RNS) might explain possible associations of green tea polyphenols and selenium with reductions in
colon cancer incidence
• Examining whether the production of prostaglandin E2 (PGE2) and/or nitric oxide (NO) is influenced by
dietary conjugated linoleic acids and their associated colon cancer risk
ADDITIONAL DIET/OBESITY-RELATED SOLICITATIONS
▲ NIH NIDDK Obesity Nutrition Centers – P03 [RFA-DK-07-001]. Up to $750K over 5 years. LOI due
May 25; application due June 22. (Foreign institutions ineligible.)
▲ The Robert Wood Johnson Foundation (RWJF) Healthy Eating Research: Building Evidence to
Prevent Childhood Obesity. Awards for 12-24 months (up to $100K) and 24-36 months (up to
$400K). Brief initial proposal due February 13. Full proposal by invitation only. (US/US Territory
institutions only.)
▲ RWJF Healthy Eating Research: Building Evidence to Prevent Childhood Obesity – Special
Solicitation . Awards for 12-24 months (up to $100K). For junior investigators in historically
disadvantaged or underrepresented communities. Brief proposal due February 13. Full proposal by
invitation only. (US/US Territory institutions only.)
NIH NCI Memory T Lymphocytes in Cancer Immunology – R01, R21
[PA-07-255, PA-06-349] (12/20, 4/3/06)
Opening Date:
Receipt Dates:
Closing Date:
January 5 (R01), May 6, 2006 (R21)
February 5, June 5, and October 5 (standard R01)
February 16, June 16, and October 16 (standard R21)
May 2, 2009
Supports basic research that is relevant to antitumor immunity and focused on memory T lymphocytes
and/or the cells and molecules that interact with them. Research may include investigations of T memory
cell differentiation, maintenance and reactivation. NCI anticipates that the results will ultimately improve the
prospects for successful cancer immunotherapies and vaccine development.
Examples of High-Interest Projects
• Developing strategies and models to investigate memory T cell generation and responses to authentic
tumor antigens.
• Developing strategies to tailor APC specifications, such as their expression of optimal combinations of
co-stimulatory ligands and inflammatory mediators, to promote tumor-specific memory T cell generation.
• Defining the interplay between stimulatory and inhibitory intracellular signals in T cells, and its impact on
memory T cell generation and function, relevant to cancer immunology.
• Defining the network of intercellular interactions critical for optimal tumor-specific T memory cell
generation and function, including interactions among T cell subsets and interactions of T cells with
cells of the innate immune system.
• Developing reagents and technologies to identify functional memory T cell subsets, to purify and
characterize those subsets, to track them and monitor their activation status in vivo, and to deliver or
inhibit signals specifically to them in vivo.
NIH NIGMS/NIA/NCI/NIDCD/NIDDK/NIEHS/NHLBI/NIMH/NINDS
Structural Biology of Membrane Proteins – R01 [PA-07-253] (12/20)
Opening Date:
Receipt Dates:
Closing Date:
January 5
February 5, June 5, and October 5 (standard)
March 6, 2009
This program solicits research that will lead to the determination of membrane protein structures at high
resolution. The scope includes not only structures of integral membrane proteins, but of complexes formed
6
between these proteins and their biological partners as well. Applications are sought for the development of
new methods of approach and the application of current methods to the solution of specific membrane
protein structures.
NIH has particular interest in innovative methods for producing membrane proteins in sufficient quantities for
characterization and structural studies. Novel approaches to cloning, expression, oligomeric assembly,
solubilization, stabilization, and purification of membrane proteins are encouraged.
NIH/AHRQ NCI Cancer Surveillance Using Health Claims-Based Data – R01, R21
[PA-07-254 ,PA-06-386] (12/20, 5/30/06)
Opening Date:
Receipt Dates:
Closing Date:
January 5, May 3, 2006
February 5, June 5, and October 5 (standard R01)
February 16, June 16, and October 16 (standard R21)
May 2, 2009
Funds research to develop and test improved methods for using health claims to assess cancer care. Cancer
surveillance may include assessment of patterns of care, quality and outcomes of care, and health
disparities across the continuum of treatment. Projects may focus on treatment and outcomes at the patientspecific level or may include influences from the provider or broader health-system level.
Submission Info:
Those applying through AHRQ must submit a detailed R&R Budget.
NIH NCI/NHLBI, NIBIB, NIDDK/NIDA/OBSSR
The Effect of Racial and Ethnic Discrimination/Bias on Healthcare Delivery – R01, R03, R21
[PA-07-206, PA-06-348, PA-06-306] (12/19, 4/12/06, 3/31/06)
Opening Date:
Receipt Dates:
Closing Date:
January 5 (R01), May 2, 2006 (R03, R21)
February 5, June 5, and October 5 (standard R01)
February 16, June 16, and October 16 (standard R03 & R21)
January 3, 2008
Goals are (a) to improve the measurement of racial/ethnic discrimination in health care delivery systems
through improved instrumentation, data collection and statistical/analytical techniques; (b) to enhance our
understanding of the influence of racial/ethnic discrimination in health care delivery and its association with
disparities in disease incidence, treatment, and outcomes among disadvantaged racial/ethnic minority
groups; and (c) to reduce the prevalence of racial/ethnic health disparities in the US through the
development of interventions.
NIH NCI/NIA Stem Cells and Cancer – R01, R21 [PA-07-187, PA-06-282] (12/19)
Opening Date:
Receipt Dates:
Closing Date:
January 5
February 5, June 5, and October 5 (standard R01)
February 16, June 16, and October 16 (standard R21)
May 2, 2008
NCI wants to stimulate research on all aspects of stem cell biology, including the molecular and
biochemical regulation of embryonic and adult stem cell behavior. While NCI encourages proposals
addressing all aspects of stem cell biology, the research objective section of the FOA focuses on the most
recent research on tumor stem cells
Examples of High-Interest Issues
• What governs the proliferation rate of normal and tumor stem cells?
• Can oncogenes and their associated mutations affect asymmetric versus symmetric divisions in stem
cells?
• Which stem cell-specific genes alter the cell cycle pathway proteins?
• Do tumor stromal cells constitute a unique tumor stem cell niche? Does the tumor stromal niche act as
a constituent of a feedback mechanism with tumor stem cells to control their growth?
• Are the phenotypes of invasion and metastasis uniquely connected to the tumor stem cell phenotype?
• Are normal resident adult tissue stem cells a special target for carcinogenic insults?
• Can new and/or better markers and assays for the isolation and enrichment of tumor stem cells be
developed?
7
•
•
Can new and/or better in vivo functional assays to identify tumor initiating cells be developed?
How do changes to stem cells or their environment due to aging affect formation of tumor stem cells or
alter their properties?
NIH NCI Decision Making in Cancer: Single Event Decisions – R01, R21
[PA-07-203, PA-05-017] (12/19, 3/31/06)
Opening Date:
Receipt Dates:
Closing Date:
January 5 (R01), May 2, 2006 (R21)
February 5, June 5, and October 5 (standard R01)
February 16, June 16, and October 16 (standard R21)
January 3, 2008
Program aims to enhance the understanding of human decision-making processes so that individuals can
make more informed and satisfying choices regarding their health. NCI encourages collaborations between
basic judgment/decision-making researchers and applied cancer control researchers that will shine light on
single-event decision-making processes pertinent to cancer prevention, detection, treatment, survivorship, or
end-of-life care.
A single-event decision is defined by NIH as a discrete decision made at a specific point in time; such
decisions are relevant at the level of the individual patient and/or healthcare provider. The scope of this
program does not include processes involving repeat decisions. (See PA-07-204 and PA-06-337 below.)
NIH NCI/NIDA/NIAA Decision Making in Health: Behavior Maintenance – R01, R21
[PA-07-204, PA-06-337] (12/19, 4/7/06)
Opening Date:
Receipt Dates:
Closing Date:
January 5 (R01), May 2, 2006 (R21)
February 5, June 5, and October 5 (standard R01)
February 16, June 16, and October 16 (standard R21)
January 3, 2008
Supports research projects designed to expand our knowledge of basic decision-making processes
underlying initiation and long-term maintenance of healthy lifestyle behaviors that may reduce one's risk of
cancer and other chronic diseases, such as diabetes, addiction, and cardiovascular disease.
NIH NINDS/NCI/NIAMS/NIDDK/NIMH Understanding and Treating Tuberous Sclerosis Complex
– R01, R03, R21 [PAS-05-085],[PAS-06-205], [PAS-06-206] (12/18, 3/8/06, 3/8/06)
Opening Date:
Application Dates:
Closing Date:
January 5 (R01), May 2, 2006 (R03, R21)
February 5, June 5 and October 5 (standard R01)
February 16, June 16 and October 16 (standard R03 & R21)
March 6,2008, March 2, 2008 (R03, R21)
Solicits proposals for research that will increase our knowledge about the mechanisms that cause Tuberous
Sclerosis Complex (TSC) and translate this knowledge into therapies. Scope includes molecular genetic,
developmental, and pathophysiological studies, preclinical therapy development, and clinical research.
Commitment:
$2M for FY 2008
NIH NINDS/NIDCD/NIA/NICHD/NCI/NIDA/NIMH Characterization, Behavior and Plasticity of
Pluripotent Stem Cells – R01, R21 [PA-07-201, PA-06-198] (12/18, 3/3/06)
Opening Date:
Receipt Dates:
Closing Date:
January 5 (R01), May 2, 2006 (R21)
February 5, June 5 (standard R01)
February 16, June 16 (standard R21)
July 6, July 2
8
Funds research on the characterization, behavior and plasticity of human and non-human stem cells;
regulation of their replication, differentiation, integration and function in the nervous system; and
identification and characterization of normal and tumor stem cells.
Encouraged Research
• Studies on characteristics that distinguish between different types of stem cells and the cellular,
molecular and genetic mechanisms that influence their lineage choices are particularly relevant.
• Investigations that explore the long-term fates of stem cell-derived populations in animal models.
• Development of methods for isolating specific cell populations, and studies that demonstrate or enhance
the safety of stem cells in treatments for neurological conditions.
NIH NINDS/NIDA/NICHD/NIA/NEI/NCI/NIAAA Interactions Between Stem and Progenitor Cells
and the Microenvironment in Vivo – R01, R03, R21 [PAS-07-189, PAS-06-207, PAS-06-208]
(12/18, 3/9/06, 3/9/06)
Opening Date:
Receipt Dates:
Closing Date:
January 5 (R01), May 2, 2006 (R03, R21)
February 5, June 5, and October 5 (standard R01)
February 16, June 16, and October 16 (standard R03 & R21)
May 2, 2008, July 2, 2007
Solicits research on the cellular and molecular signaling between the local environment within organisms
and stem and progenitor cells that are either introduced as transplants or normally resident within host
tissues and organs. The objective is to promote a thorough exploration and characterization of the bidirectional communication between multipotent cells and the three-dimensional local milieu or niche that
they encounter in vivo under normal and compromised states, such as with aging or following injury, disease
or drug exposure.
NCI is interested in the role of neural tumor stem cells in the progression and development of tumors of the
nervous system, with particular emphasis on interaction of the neural tumor microenvironment on the
proliferation and differentiation of neural tumor stem cells.
Commitment:
$2.7 M
NIH NINDS/NCI Understanding and Preventing Brain Tumor Dispersal – R01, R21
[PAS-07-196, PAS-06-201 ] (12/18, 3/2/06)
Opening Date:
Receipt Dates:
Closing Date:
January 5 (R01), May 2, 2006 (R21)
February 5, June 5 (standard R01)
February 16, June 16 (standard R21)
July 6, July 2
Proposals should focus on: (a) determining the causes of brain tumor dispersal; (b) understanding the
interactions of migrating tumor cells with normal brain elements; or (c) developing interventions that target
migrating tumor cells. Analysis of either pediatric or adult brain tumors is appropriate.
Encouraged Investigations
• Studies that apply insights from other fields (e.g. developmental neuroscience, glial cell biology, stem or
precursor cell biology) to the analysis of tumor spread.
• Translational studies using cell or animal models of brain tumor migration to test possible therapeutic
interventions.
• Interdisciplinary collaborations, as well as interactions between basic scientists and clinicians.
Commitment:
$1M/year (NINDS); NCI’s level of funding undetermined
NIH NCI Correlative Studies with Specimens from Multi-Site Trials – R01
[PA-07-177, PA-06-296 ] (12/15, 3/29/06)
Opening Date:
Receipt Dates:
Closing Date:
January 5 (R01), May 2, 2006 (R21)
February 5, June 5, and October 5 (standard R01)
February 16, June 16, and October 16 (R21)
May 2, 2008, March 2, 2008
9
Provides researchers with tumor specimens collected during multi-institutional clinical trials. By sponsoring
this opportunity, the NCI Cancer Therapy Evaluation Program (CTEP), the Cancer Diagnosis Program
(CDP), and the Cancer Biomarkers Research Group (CBRG) advance three objectives:
(1) providing investigators with support for correlative studies using trial-related tumor specimens to
compare genetic variations and molecular changes from the cell nucleus, the cytosol, and the cell
surface and extracellular matrix to tumorigenesis and progression, drug resistance, therapeutic
effectiveness of interventions, and patients' clinical outcomes;
(2) deciphering mechanisms and evaluating new cancer interventions by utilizing these tumor tissue
resources and accumulated clinical trial results for better cancer risk assessment, early detection, and
prediction of response to various cancer therapies and prevention strategies; and
(3) promoting translational research and fostering collaborations between basic researchers and clinical
investigators from academia, private industry, and nonprofit organizations to ensure that new findings
will be rapidly translated into clinical practice.
Proposed research should focus also on correlations between biologic features of tissue specimens (from an
NCI Cooperative Group or other large multi-institutional clinical trials) and patient outcomes.
Submission Info:
If tissue specimens will be obtained through a NCI Cooperative Group, the
associated chairperson must provide a letter confirming the provision of
specimens should the application be funded.
NIH NCI/NEI/NHLBI/NHGRI/NIA/NIAAA/NIAID/NIAMS/NICHD/NIDCD/NIDCR/NIEHS/NIGMS/NINR/
NCCAM/OCS Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual
Senior Fellows – F33 [PA-07-172] (12/15)
Receipt Dates:
Closing Date:
January 25, May 25, and September 25 (standard)
January 9, 2009
These training fellowships enable experienced scientists to either make major changes in the direction of
their research careers or broaden their scientific background by acquiring new research capabilities
as independent investigators in fields relevant to the missions of participating NIH Institutes and Centers.
Award:
Applicant/Research
Restrictions:
Submission Info:
Up to 2 years. Includes stipend, living expenses, and institutional expenses to cover
health insurance, etc. Stipend schedule at http://grants.nih.gov/training/nrsa.htm.
• Applicant must be a citizen or noncitizen national of the United States or have
been lawfully admitted for permanent residence.
• Applicant must have a minimum of 7 years postdoctoral experience and an
established career as an independent researcher.
• Applicant cannot have more than 2 concurrent competing NIH applications
pending review.
• Proposed research must be supervised by an active sponsor.
• Research must fall within scientific purview of sponsoring NIH Institute.
• Funds may not be used to support studies leading to a terminal healthprofessional degree.
• Funds may not used to support the clinical years of residency training.
Electronic submissions begin September 25.
NIH NHLBI/NICHD/NIAMS/NCI/NCCAM/NIBIB/NINR Pathogenesis and Treatment of
Lymphedema and Lymphatic Diseases – R01 [PA-07-165] (12/14)
Opening Date:
Receipt Dates:
Closing Date:
January 5
February 5, June 5 and October 5 (standard R01)
December 31, 2006
This program aims to stimulate research on the lymphatic system; to characterize its function on the
molecular, cellular, tissue, organ, and intact organism levels and also the pathophysiologic mechanisms that
cause disease; to develop new methods for imaging and/or quantitating lymph flow; and to discover new
therapeutic interventions, including nursing, complementary and alternative treatments. Relevant studies
include the application of developmental biology and genetics to identify and characterize processes
important for organization and regulation of the lymphatic system. Such knowledge will help improve early
diagnosis of affected individuals, the choice and timing of treatment, and genetic counseling. Research is
also needed on disorders of skin and subcutaneous tissue due to chronic lymphedema and lymphedema
resulting from cancers or cancer treatment.
10
Investigators should consider how to make experimental results available to other scientists for data mining
and how to make archived data interoperable with commercially available software.
AIDSRELATED
╬ NIH NCI/ Research on Malignancies in AIDS and Acquired Immune Suppression – R01, R03
[PA-07-173, PA-06-338] (12/15, 4/7/06)
Opening Date:
Receipt Dates:
Closing Date:
January 5, May 2, 2006
May 1, September 1 (standard AIDS-related)
December 2
Fosters research that will improve our understanding of the biological basis of the development and
progression of cancer in the context of HIV infection/AIDS or acquired immune suppression not associated
with HIV infection, such as from organ transplantation. NCI invites novel approaches to discovery and
preclinical development of new therapeutic agents and biomarkers for early diagnosis and monitoring of
disease progression. It also encourages molecular epidemiologic studies of the role of chronic latent viruses
and their interaction with one another or with environmental factors in the context of acquired immune
suppression or HIV infection leading to the development of tumors or lesions with oncogenic potential.
╬ ▲ NIH NICHD/NIMH Integration of Food and Nutrition into Prevention, Care, and
Treatment of HIV Infection and AIDS – R03 [RFA-HD-07-001] (12/22)
LOI Date:
Application Date:
Closing Date:
February 28
March 29
March 30
Encourages new and experienced basic scientists, epidemiologists and clinical investigators to evaluate the
impact that new guidelines and programs aimed at improving the diet and nutritional status of people
infected and affected by HIV/AIDS have on programs aimed at caring for and treating them. Intends to
stimulate a multidisciplinary approach to this under-researched area and to form a basis for future research
and clinical care.
Award:
Renewable?
Two years, $50K annual direct costs ($400K available to support 6-8 projects)
No
ADDITIONAL AIDS-RELATED SOLICITATIONS
╬ NIH NINDS NIDA NIMH Non-Human Lentiviral Models of the Neurological Complications
of AIDS –R01, R03, R21. Intended commitment of $2.15M in FY 2006
(12/18,3/24/06,3/24/06)
╬ NIH NIDA Non-Injection Drug Abuse and HIV/AIDS – R01, R03, R21. Estimated $2M for 3-7
projects in FY 2007 (12/7,12/21,12/21)
Susan G. Komen Interdisciplinary Breast Fellowship Program
Opening Date:
Application Date:
Start Date:
December 1, 2006
February 15
May 1
Designed to improve patient care by:
•
•
•
preparing highly motivated, talented and compassionate physicians for careers devoted to serving the multispecialty needs of the breast cancer patient;
offering interdisciplinary curriculum integrated into a comprehensive program; and
providing special emphasis on enhancing the physician’s understanding of the patient with benign and
malignant breast disease while developing a better treatment environment for future patients.
Program should include a coordinated curriculum and clinical rotation schedule for training that enhances the
care of the patient as well as the total person. Should allow for concentration in fellow’s area of specialty, but
also provide rotations in or exposure to areas including breast imaging; breast surgery; community service and
outreach; genetics; medical oncology; pathology; plastic and reconstructive surgery; psycho-oncology; radiation
oncology; and research.
FY 2007 RFA (PDF)
11
Award:
Submission Info:
Two-year total of $90K. Can be use to support either (a) one fellow for 2-year
program or (b) two consecutive 1-year fellows.
Electronic applications only. Use proposalCENTRAL: https://v2.ramscompany.com/
ADDITIONAL SOLICITATIONS (DEADLINES BEFORE FEBRUARY 15)
FDA Orphan Products Grant Program [RFA-FDA-OPD-2007]
Protocol Due Date:
Application Date:
January 8
February 7
Supports clinical development of products for use in rare diseases, or in conditions where no current therapy
exists, or where the product will improve the existing therapy. Grants are for clinical studies on safety and/or
effectiveness that will either result in, or substantially contribute to, market approval.
Protocols that would otherwise be exempted from Investigational New Drug (IND) or Investigational Device
Exemption (IDE) regulations must be conducted under an active IND/IDE. (For this program, only medical foods
that do not need premarket approval and medical devices that are classified as a nonsignificant risk (NSR)
remain exempt.) For additional information about IND/IDE regulations, see below.
Award:
Inst. Restrictions:
Protocol Info:
Up to 3 years of annual total costs (direct + indirect) of $200-350K (10-12 new grants
expected in FY2008)
DHHS agencies excluded
The FDA Center for Drug Evaluation and Research (CDER) outlines the
Investigational New Drug Application (IND) Process. Consult the Center for Devices
and Radiological Health (CDRH) for Device Advice.
Ellison Medical Foundation (EMF) Senior Scholar Award in Aging
LOI Date:
Application Date:
Notification:
Start Date:
January 9
July 12 – By invitation (in June)
August
September
Will support established investigators in developing creative research programs, especially those investigators
not conducting aging research or wishing to develop new research programs in aging. Intended to stimulate
new research that has rigorous scientific foundations, but may not be funded adequately, because of its
perceived novelty, its high risk, or the fact that it is from an area where traditional research interests absorb
most funding.
Award:
Research
Restrictions:
$150K in direct costs with indirect costs added for up to 4 years. Funding for
Years 2-4 contingent upon satisfactory progress report.
Specific documentation required for research involving human subjects, animal
subjects, research collaborations with foreign institutions, biosafety issues, or
embryonic stem cells.
Goldhirsh Foundation National Brain Tumor Research Awards
LOI Date:
Application Date:
Notification Date:
Start Date:
January 10 (noon EST)
April 17 – By invitation (in March)
June 1
July 1
Seeks to investment in pediatric and adult brain tumor research that will lead toward developing more effective
treatment for malignant diffuse glioma tumors. This program solicits LOIs from investigators working in the
continuum between basic research and clinical application. Examples of funding areas include oncogenomics
and proteomics, genetically engineered models, the discovery and testing of small molecule therapies, unusual
drug delivery systems, or improved brain imaging techniques. The Foundation also encourages submission of
research projects at the interface of developmental biology and cancer along the stem cell to glial axis.
Applicant may collaborate with investigators from other institutions, including nonprofits. Eligibility not limited to
those investigators currently working in brain tumor research.
12
LOI must specify whether you are applying for the three-year ($600K) or pilot ($100K) award.
Award:
Applicant
Requirements:
Research
Restrictions:
Review:
Previous Recipients:
•
$600,000 awarded as $200,000 a year for 3 years and includes 10% indirect
costs (3 awards to be made); $100,000 for 1-year pilot study.
• Must have earned MD and/or PhD degree(s) or equivalent degree.
• Must have attained position of at least Assistant Professor or equivalent at a
US-based 501(c)(3) or equivalent not-for-profit Canadian institution.
• Projects must be relevant to malignant diffuse gliomas, i.e. diffuse
astrocytomas, oligodendrogliomas and oligoastrocytomas, including
glioblastoma.
• Projects in benign/WHO grade I gliomas, nonglial neuroepithelial tumors,
meningeal tumors, nerve sheath tumors, CNS lymphomas, germ-cell tumors
and tumors of the sella region are beyond the scope of the grant program focus.
• Projects that characterize genes and gene products of normal cellular
development are not eligible, nor are epidemiological studies.
Two criteria, the former being preeminent:
(1) Quality and originality of the research project and its future potential to improve
treatment of malignant diffuse glioma tumors
(2) Qualifications of the candidate and prior experience in conducting innovative
research
Evaluation by multidisciplinary scientific advisory committee :
http://www.goldhirshfoundation.org/scientific_advisory_board.htm
http://www.goldhirshfoundation.org/grant_recipients.htm
DOD BCRP Concept Award [W81XWH-06-BCRP-CA] (12/22/06)
(http://cdmrp.army.mil/funding/bcrp.htm)
Pre-Application Date:
(Full) Application Due:
January 23
February 13
March
May
Part of the Breast Cancer Research Project (BCRP), this award is designed to fund the exploration of a highly
innovative new concept. Presentation of preliminary data is not allowed. Proposals must describe how the new
concept could create an entirely new avenue for investigation and how it is relevant to breast cancer.
Award:
Review:
Maximum of $75,000 over a 1-year period, plus indirect costs as appropriate. In FY
2007, the Office of the Congressionally Directed Medical Research Programs
(CDMRP) was appropriated $8MM to fund 75-80 Concept Awards.
Two-tiered process involves a peer review group and an integrated review panel.
Both are discussed and evaluation criteria are presented on pp.11-13 of the
Program Announcement (PDF). Peer reviewer panels are comprised of both
scientific/technical experts and consumers. Rosters of previous peer review panels
are available at http://mrmc-rad6.army.mil/bcrp/peerreviewers.htm. A roster for the
FY2006 BCRP Integrated Review Panel can be found at http://mrmcrad6.army.mil/bcrp/panel06.htm.
DOD BCRP Multidisciplinary Postdoctoral Award [W81XWH-06-BCRP-MPA2] (12/22/06)
(http://cdmrp.army.mil/funding/bcrp.htm)
Pre-Application Date:
Application Date:
Peer Review:
Programmatic Rev:
January 23
February 13
March
May
Enables exceptional recent graduates with medical or other doctoral degrees to obtain significant training and
experience in 2 or more discrete disciplines in order to pursue an independent career at the forefront of breast
cancer research. Proposals should emphasize a multidisciplinary program in which major disciplines are
integrated into a common research and training environment. For this award, major discipline areas include:
basic biological (including pathology); clinical; chemical; social and behavioral; engineering, physical and
mathematical; and public health and health-services related.
Award:
Three (3) years of $150K direct costs (and indirect costs added); portion devoted to
13
PI/PD Requirements:
salary can increase yearly ($53K to $57K). About $5M expected to fund 8-10
awards.
• Must have a doctoral degree; should not have been in the laboratory or
research setting associated with the proposed research for more than 2 years at
the time of submission, and should total less than 5 years of postdoctoral
research experience (excluding clinical residency or fellowship training).
•
Review:
•
Must have/obtain a primary mentor and must identify an additional mentor
for each other major discipline.
Must attend biennially scheduled 3½-day DOD Era of Hope meeting
Pages 21-25 of the announcement list evaluation criteria.
NIH NINR/NCI Symptom Clusters in Cancer and Immune Disorders – R01, R21
[PA-07-074, PA-07-009] (11/20/06, 10/13/06)
Opening Date:
Receipt Dates:
Closing Date:
January 5 (R01), December 1, 2006 (R21)
February 5, June 5, and October 5 (standard R01)
February 16, June 16, and October 16 (standard R21)
January 3, 2008
Solicits applications from organizations that propose to (a) identify and assess biobehavioral characteristics
of symptom clusters, or (b) design and test interventions that lead to clear outcomes. A rationale for the
choice of a symptom cluster is needed, not just co-occurrence of two or more symptoms. Studies at any
point in the disease trajectory, or during the survivorship period are encouraged. Ultimate goal is to build a
body of science in symptom cluster identification and intervention in cancer and in acquired or autoimmune disorders.
NIH NCI Established Investigator Awards in Cancer Prevention and Control  K05
[PAR-05-145] (7/28/05)
Receipt Dates (new):
Closing Date:
February 12, June 12, and October 12 (standard)
July 2, 2008
Provides qualified cancer research scientists in the fields of cancer prevention, control, behavioral, and/or
population sciences with protected time to devote to research and to mentoring of new investigators.
Award:
Restrictions:
Renewable?
Submission Info:
•
The award provides the recipient with annual salary support (up to the current
Federal salary limit) for 25-50% effort, plus fringe benefits. The award also
provides $25,000 per year in research-related expenses. Duration of 3-5 years.
• Candidate must justify request for K05 support in terms of need for protected
time to devote to research and mentoring.
• Candidate must have track record of successful independent research funding
and mentoring. At the time of the K05 award, candidate must have obtained
independent R01 research funding or its equivalent in a research area related to
cancer prevention and control.
• Candidate may not concurrently apply for or have pending another NIH career
development award.
• Only 2 revisions of a K05 application will be accepted.
• Foreign institutions are not eligible to apply.
• Candidate must possess a health professional or research doctoral degree (or
equivalent).
• Candidate must be US citizens, citizen nationals, or individuals lawfully admitted
for permanent residence.
Up to 5 years
Electronic submissions required as of June 12, 2007.
NIH NCCAM/ODS Complementary and Alternative Medicine Career Transition Award  K22
[PAR-05-129] (6/23/05)
Receipt Dates (new):
Closing Date:
February 12, June 12, and October 12 (standard)
September 2, 2008
This biphasic program is designed for outstanding advanced postdoctoral research scientists during their
14
transition to independence. It provides support for up to 1 year of postdoctoral research training and 3 years of
research support as an independent investigator. Candidates must propose research in complementary and
alternative medicine (CAM) for the independent investigator phase of this award.
Amount:
Restrictions:
Submission Info:
Varies
• Must have clinical or research doctorates and at least 1 year but no more than 5
years of postdoctoral research training.
• Must be supported by an NIH T32 or F32 grant or Intramural Research Training
Award Fellowship. Individuals supported by other prestigious national or
international individual postdoctoral awards will also be considered.
• Applicants may submit only one K22 application, and may not simultaneously
submit applications for other career awards (K-series mechanisms). Applicants
are permitted to submit revised K22 applications.
• Grantees will be expected to devote 100% of their time during the postdoctoral
phase and a minimum of 75% of their time during the independent phase to the
proposed research.
• Must not have been a PI on either an NIH research grant (such as R29, R01,
P01, other K awards, or subprojects) or a peer-reviewed non-NIH research
grant intended for faculty members.
Electronic submissions required as of June 12, 2007.
NIH NIDA/NCI Cross-Disciplinary Translational Research at NIH – R01, R03, R21
[PA-07-109, PA-06-322, PA-06-321] (12/6/06, 4/5/06, 4/5/06)
Opening Date:
Receipt Dates:
Closing Date:
January 5 (R01), May 2 (R03, R21)
February 5, June 5, and October 5 (standard R01)
February 16, June 16, and October 16 (R03, R21)
May 2, 2007 (R01), May 31, 2007
Supports research that furthers the translation of existing knowledge into treatment and treatment practice,
or research that, in and of itself, will readily translate to clinical research or practice. Scope includes a range
of activities designed to yield a knowledge base for the development of novel, efficacious drug abuse
prevention or treatment interventions.
Potential Research Goals
• Laboratory studies designed to discover whether neurochemical or related mechanisms observed in
preclinical science can serve as important targets for the treatment of drug addiction.
• Laboratory studies, especially phase I clinical studies, with human volunteers that evaluate drugs that
are currently being used to treat non-addiction disorders, but whose preclinical effects indicate possible
utility for treating drug abuse.
• Discovery and evaluation of animal models that permit further evaluation of candidate therapeutics,
such as using animals that have been modified genetically, chemically, or through any intervention, that
captures critical features of drug abuse.
• Development and testing of clinical tools for screening, assessment, diagnosis, and treatment matching
to improve the targeting of treatment services.
• Development of models of longitudinal care for defined populations, based on clinical research of longterm patterns of drug use and long-term patterns of response to prevention and treatment.
• Using discoveries from the basic biological, psychological and social sciences to develop and test
innovative drug abuse prevention interventions.
(More are listed in the program announcement.)
Doris Duke Charitable Foundation (DDCF) Clinical Scientist Development Award
(See Supplement.)
NSF BIO/MCB Cluster Grants
Receipt Date:
January 12
When preparing these proposals, it is crucial to emphasize that you are requesting funding for basic research
that is not appropriate for NIH—i.e., that you de-emphasize the healthcare benefits. The long-term benefits
15
sought by NSF are an increased understanding of—or improved technologies to probe—molecular and cellular
processes. In addition to specific findings, the agency usually wants results/ technologies that advance our
understanding of, and can be applied to, more general biological processes.
In Washington, DC, frontier problems involving biology/biomedicine are considered both high priority and
beyond the scope of a single discipline. Primarily through cross-cutting programs, NSF is trying to increase its
biological research profile. However, the agency in no way wants investigators using its basic research dollars
to support health-related projects that should be funded by NIH. A look at the relative budgets for basic and
health-related research shows you why.
R&D Budget by Federal Agency, FY 2005-2007 ($M)
Agency
NSF
DOD
Subtotal
NIH (NCI)
FY 2005 (actual)
4.1
3.4
7.5
27.6 (4.8)
FY 2006 (preliminary)
FY 2007 (proposed)
4.2
3.3
7.5
4.5
3.8
8.3
27.7 (4.7)
27.7 (4.7)
Source: Research and development Funding by Budget Function: FY 2005-2007
NSF-07-303, Dec 2006, http://www.nsf.gov/statistics/nsf07303/
GENERAL INFORMATION○
•
•
•
•
•
•
•
•
Dollar amounts represent direct costs.
R01 awards are for unspecified amounts dependant on available funding and
the nature of applications received; they are renewable.
R03 awards are up to of $100K over two years and are nonrenewable.
R21 awards are up to $275K over two years and are nonrenewable.
NIH AIDS-related proposals are associated with the standard receipt dates
May 1, September 1, and January 2 (extended to January 3 for this year).
Applicants/Institutions can submit more than one application.
All applicants with the skills, knowledge and resources necessary to perform
proposed research are eligible.
CORRECTION
The first newsletter listed incorrect
eligibility requirements for the
program on Diet, Epigenetic
Events, and Cancer Prevention
(R01). There are no specific
restrictions/
requirements, except that the
applicant or set of applicants need
demonstrate experience with
nutrition, cancer prevention, and
epigenetic research.
No institutional restrictions other than the general NIH standards apply.
○
Applicable unless otherwise specified
2
No. 2, January 2, 2007
Heidi Davis, Editor
Office of Grants and Development
[email protected]
16